Yahoo Search Búsqueda en la Web

Resultado de búsqueda

  1. PMID: 31901449. DOI: 10.1016/j.clinph.2019.11.002. Abstract. A group of European experts reappraised the guidelines on the therapeutic efficacy of repetitive transcranial magnetic stimulation (rTMS) previously published in 2014 [Lefaucheur et al., Clin Neurophysiol 2014;125:2150-206].

  2. 1 de feb. de 2020 · In November 2014, a consensus paper was issued in Clinical Neurophysiology (Lefaucheur et al., 2014), reporting guidelines established by a group of European experts on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS), based on evidence published until March 2014.

  3. This guideline paper provides an up-date on the clinical use of transcranial magnetic stimulation (TMS). The clinically relevant technical and physiological principles of TMS are outlined. A detailed description how to examine corticomotor conduction to the hand, leg, trunk and facial muscles is presented.

  4. Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4–6 weeks (20–30 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Disorder in adults who have not responded to prior antidepressant medications.

  5. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol. 2021 Jan;132 (1):269-306. doi: 10.1016/j.clinph.2020.10.003. Epub 2020 Oct 24.

  6. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) Clin Neurophysiol. 2014 Nov;125 (11):2150-2206. doi: 10.1016/j.clinph.2014.05.021. Epub 2014 Jun 5. Authors.

  7. 1 de ene. de 2021 · The meeting intended to update the ten-year-old safety guidelines for the application of transcranial magnetic stimulation (TMS) in research and clinical settings (Rossi et al., 2009).